**Single Agreement**

**HEALTHCARE INSTITUTION, CARE HOME OR HEALTH CENTRE /COMPANY**

**relating to the performance of the industry-sponsored Research Protocol involving humans**

Clinical Trial No. ***redacted***

**EudraCt No redacted**

***Coordinating Institution Version***

**BETWEEN THE UNDERSIGNED:**

**Of the one part,**

**The institution redacted**. registered with FINESS [*Fichier National des Etablissements Sanitaires et Sociaux* (National Registry of Healthcare and Social Facilities)] under No. redactedwith SIRET (French company registration) code and with registered office at **represented by** …. and hereinafter referred to as “The Coordinating Institution”;

**Of the other part,**

**The company** … registered with the Trade and Companies Registry of .under number …,

**with registered office at** …, United States, and hereinafter referred to as “The Company”; represented in …

**AND/OR**

**The company** …, and its affiliates, authorised fully or partially to execute this agreement for and on behalf of the Company and hereinafter referred to as “the CRO” (Contract Research Organisation).

The Coordinating Institution, the Company or the CRO and, if applicable, the Third-Party Organisation, are hereinafter referred to individually or jointly by the terms “the Party” or “the Parties”.

**In view of:**

Articles L.1121-16-1 and R.1121-4 of the French Public Health Code;

The rules of Good Clinical Practice of 24 November 2006;

The Code of Medical Ethics (Articles R.4127-1 to R.4127-112 of the French Public Health Code);

The approvals, authorisations and certifications required to conduct the Research;

**RECITALS:**

The Company has taken the initiative to conduct the research governed by the Protocol entitled and referenced as follows: “A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD(Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia)”, hereinafter referred to as ”the Research”. The protocol and its amendments are hereinafter referred to as “the Protocol”.

The Research:

* shall be conducted in the Coordinating Institution signatory to this agreement,
* has been submitted with an application for authorisation with the *Agence Nationale de Sécurité des Médicaments et des Produits de Santé* [National Agency for Medicines and Health Products Safety] (ANSM) and the number shall be provided by the Company to the Healthcare Institution prior to opening of the sites,
* has been submitted to the *Comité de Protection des Personnes* [Ethics Committee] of Sud-Est III and the opinion shall be provided by the Company to the Coordinating Institution prior to opening of the sites,
* is for a provisional term of 24 months, from 1st September 2021,
* is covered by an insurance contract with Lloyd’s Insurance Company S.A., Policy No SYB21032199A
* is based on the provisional enrolment of 3patients at the Coordinating Institution.

Given that the Coordinating Institution signing this agreement has the knowledge, experience, availability and material capacity to conduct the above-mentioned Research, expects to be able to enrol the required number of patients meeting the inclusion criteria of the Protocol in the time allowed, and is willing to conduct the Research on its premises;

It having been previously specified that any element, information, document, product or materials supplied by the Company under this agreement must be used only for the purposes of the Research which is the subject of this agreement and in accordance with the Research Protocol;

**THE FOLLOWING IS AGREED:**

**CLAUSE 1: PURPOSE**

The purpose of this agreement is to determine the services provided by the Coordinating Institution to the Company, in the context of the Research, the terms under which they are provided and the additional costs which they will generate, hereinafter referred to as “Costs” and “Additional Costs” of the Research.

The services include:

* the provision by the Coordinating Institution of the human, material and technical resources necessary for carrying out the Protocol;
* the performance of tasks necessary for conducting the Research in terms of clinical investigation;
* the performance of clinical investigation tasks.

The Company will not enter into any other contract for a consideration with the coordinating investigator for the performance of the services which are the subject of this agreement.

**CLAUSE 2: DEFINITIONS**

Additional Costs relate to the treatment of the patient or of the healthy volunteer and required for the carrying out of the Protocol. This means the procedures necessary for the Research, in addition to those mentioned in the recommendations for Good Clinical Practice validated by the *Haute Autorité de Santé* [French National Authority for Health] for the treatment concerned, when they exist, and which are not chargeable to the health insurance fund or to the patient.

Costs are made up of all other additional costs relating to the carrying out of the Protocol, in particular investigative tasks necessary for the Research and administrative and logistical tasks in connection with the Research.

Coordinating Institution: the institution, nursing home or health centre establishing the agreement and which undertakes, together with the investigator, to validate the list of Additional Costs proposed by the Company or to issue counter-proposals drawing on the investigator’s expertise.

The list of Additional Costs and Costs, and the calculation thereof, shall be identical for all the Institutions associated with the Research, in proportion to the tasks performed.

Associated Institution: an institution, nursing home or health centre participating in the Research by the inclusion of patients and providing one or more investigators or other research staff.

Coordinating Investigator: The investigator appointed as such by the sponsor in accordance with Article L. 1121-1 of the French Public Health Code.

Result(s): means any documents, data, information, reports, analyses, data files, data bases and any work resulting from the Research and, more broadly, from this Agreement irrespective of their form, medium or writing method.

**CLAUSE 3: CONTACTS OF THE PARTIES / CORRESPONDENCE**

Any letters, dispatches or notifications whatsoever pursuant to this agreement shall be sent for the attention of the administrative and scientific contacts of each of the Parties, by means of the contact details provided in Annex 1.

It shall not be necessary to add an amendment in the event of change of administrative and/or scientific contact during the research, provided that the other Party or Parties are given prior written notice thereof.

**CLAUSE 4: UNDERTAKINGS OF THE COORDINATING INSTITUTION**

The Coordinating Institution undertakes to comply with all the legislative and regulatory provisions applicable in France, with this agreement and with the research protocol.

The Coordinating Institution shall ensure compliance with the provisions of this agreement and the Research protocol by all Research staff under its supervision and control.

The Coordinating Institution shall ensure the proper organisation and performance of the tasks, which are the subject of this agreement, including the smooth running of the Research conducted under the responsibility of its investigator.

The Coordinating Institution shall hold the Company harmless against loss or damage incurred (including as a result of fire or water damage) by patients and staff taking part in the Research, as well as by the drugs, products, materials and equipment, on the premises made available for the conduct of the Research, as a result of its activity or equipment or the actions of its staff.

This agreement is made in consideration in particular of the Coordinating Institution, which shall not sub-contract the services entrusted to it without the prior written agreement of the Company. In the event of authorised sub-contracting, the Coordinating Institution shall remain liable for any breaches on the part of its sub-contractors vis-à-vis the other Parties.

**CLAUSE 5: [if applicable] UNDERTAKINGS OF THE THIRD-PARTY ORGANISATION**

The Third-Party Organisation undertakes to comply with all legislative and regulatory provisions applicable in France.

The Third-Party Organisation undertakes to take all reasonable care and all professional diligence necessary for the performance of the tasks entrusted to it under this agreement and the Protocol, and in accordance with the current regulations and standards.

The Third-Party Organisation undertakes to have available throughout the Research all the resources necessary for the performance of its duties, as defined in Annex 3.

In this connection, the Third-Party Organisation declares that it has taken out civil liability insurance with an insurance company known to be solvent, covering the financial consequences of its professional and civil liability for any direct and indirect damage caused by it in or on the occasion of the performance of this agreement.

This agreement is made in consideration in particular of the Third-Party Organisation, which shall not sub-contract the services entrusted to it without the prior written agreement of the Company. In the event of authorised sub-contracting, the Third-Party Organisation shall remain liable for any breaches on the part of its sub-contractors vis-à-vis the other Parties.

**CLAUSE 6: UNDERTAKINGS OF THE COMPANY**

The Company undertakes to comply with all legislative and regulatory provisions applicable in France.

* It shall provide the management of the Coordinating Institution with the following documents and information: Protocol (in French or in English), Protocol synopsis in French, [copy of the delegation of authority if supervised by a CRO], name and title of the person signing the agreement and the reference and address for invoicing.
* It shall provide the Coordinating Institution with the proposed list of Costs, Additional Costs and Compensation.
* It shall inform the Coordinating Institution if the duration of the Research changes from the duration initially expected, as stated in the Recitals to this agreement.
* It shall compensate the Research-related expenses, Costs and Additional Costs, as set out in the Annex to this agreement.

**CLAUSE 7: PROCEDURES FOR INVOICING AND PAYMENT**

The fixed costs, as defined in Annex 2, shall be payable by the Company upon signing this agreement.

The other costs, as defined in Annex 2: shall thereafter be covered by the Company on presentation of a revenue order or invoice issued by the Coordinating Institution, on the basis of the information shared and transmitted by the Company and the investigator to the Institution (number of patients screened, number of patients included, visits and procedures actually carried out).

The Company, jointly with the investigator, shall inform the Coordinating Institution of the completion of the Research and shall communicate to it the information necessary for the final calculation of additional costs due.

**CLAUSE 8: COMPENSATION**

In addition to the Costs and Additional Costs, the Company may decide to pay to the Coordinating Institution or, if applicable, to the Third-Party Organisation compensation for the expected quality of the data resulting from the Research. This compensation does not offset the services of the Coordinating Institution already defrayed as Costs and Additional Costs.

**CLAUSE 9: RIGHTS TO THE RESULTS, CONFIDENTIALITY, PUBLICATIONS**

## 9.1 Confidentiality

The Coordinating Institution or, if applicable, the Third-Party Organisation shall treat all information and documents received from the Company hereunder, as well as the results of the Research, as strictly confidential.

This obligation covers any information and communication media supplied by the Company or on behalf of the Company and, in particular, information and data concerning the product which:

* were not already in the possession of the Coordinating Institution or the investigator and/or the Third-Party Organisation prior to their disclosure by the Company;
* were not available to the public, excluding information which would have become publicly available without any fault of the Coordinating Institution or of the investigator and/or the Third-Party Organisation or of the group of persons working on the Research;
* have not been communicated to the Coordinating Institution or the investigator and/or the Third-Party Organisation by a third party entitled to disclose them.

Confidential information and documents also include the clauses of this agreement, the Protocol and any Research information and data and, in particular, the case report forms and all the information they contain.

However, the confidential information may be disclosed with the written consent of the Company or at the request of the competent authorities, or in relation to publications as defined below.

The Company shall treat as strictly confidential any information relating to the Coordinating Institution or the investigator and/or the Third-Party Organisation to which it may have access in conducting the Research which is the subject of this agreement.

The undertaking of confidentiality of the Parties shall apply throughout the term of this agreement and for as long as the confidential data are not in the public domain.

## 9.2 Intellectual property rights

The Results of the Research shall be the whole and exclusive property of the Company, which may use them freely.

The Company may file or cause to be filed on its own behalf, or on behalf of such person as it shall designate, any patent application concerning the results of the Research or including them in full or in part and, more generally, protect them as it sees fit.

The Coordinating Institution and/or the Third-Party Organisation undertake(s) to take all necessary measures to ensure that the ownership of the results of the Research can be vested in the Company.

Any intellectual property rights held by one Party prior to the signature date of this agreement shall remain the property of that Party, and this agreement shall not affect the said rights.

## 9.3 Publication

The Coordinating Institution and the investigator and/or the Third-Party Organisation expressly agree that the results of the Research shall be published exclusively under the coordination of the Company so as to include the results of all participating sites in the publication.

In accordance with Article R. 5121-13 of the French Public Health Code, the Research may not be made the subject of any publication or any written or verbal communication by the Coordinating Institution or the investigator and/or the Third-Party Organisation without the prior written consent of the Company.

Requests for publication or communication should be made to the (administrative and scientific) contacts of the Company by registered letter with acknowledgment of receipt. The Company undertakes to reply thereto as quickly as possible.

## 9.4 Use of name and/or logo

The logo and/or name of the Parties may only be used outside of the formalities required for the conduct of the Research with the written consent of the other Party. However, it will be possible to publish names or logos when required under the regulations.

**9.5 Audit**

Provided that they have been informed at least fifteen days prior to the intervention on site of the auditor’s identity, the dates of the audit and its content, the Coordinating Institution and the investigator undertake to assist the Company or its agent in the successful completion of any audit or inspection, on the Research which is the subject of this agreement, in accordance with all the legal provisions governing Good Clinical Practice.

**CLAUSE 10: EFFECTIVE DATE - TERM - CANCELLATION AND TERMINATION OF THE AGREEMENT**

This agreement, of which the Annexes form an integral part, shall be effective as of the date of its signature by the Parties. It is binding on the Parties until completion of the Research as defined in the last paragraph of Article 7 of this Agreement.

In the context of the Research, any opening of new sites, in an associated institution, nursing home or health centre, shall take place on the basis of this Agreement.

This Agreement may be terminated by any one of the Parties before its expiry date, by registered letter with acknowledgment of receipt, in the event of a technical, methodological or scientific event calling into question the continuation of the Research undertaken. It shall terminate automatically if the competent authority prohibits the performance of the Research.

The term of the Research may be amended by prior written agreement between the Parties without the need for an amendment to be drafted.

In the event of early interruption:

* any variable costs incurred by the Coordinating Institution shall be payable by the Company in proportion to work carried out to the day of termination of the Agreement,
* the fixed costs mentioned in Annex 2 to this Agreement shall be payable in any event, including in the absence of inclusions at the end of the Research.

In the event of serious or deliberately repeated breach in the performance of the Research, quality control or an audit, the Company or the Coordinating Institution shall be informed immediately and may terminate this Agreement automatically, without prior notice or compensation.

This Agreement may be terminated by one of the Parties in the event of non-performance by the other Party of one or more of the obligations contained in its various clauses. Such termination shall only take effect three months after dispatch by the complainant Party of a registered letter with acknowledgment of receipt stating the reasons for the complaint, and having remained without any response, unless during that period the defaulting Party has fulfilled its obligations or has provided proof of having been prevented from doing so following a case of force majeure.

**CLAUSE 11: ANTI-CORRUPTION - TRANSPARENCY**

The Coordinating Investigator expressly undertakes throughout the performance of the agreement to comply with current laws and regulations and, in particular, the provisions relating to the prevention of and fight against corruption.

The Coordinating Investigator certifies that he has not directly or indirectly offered or authorised any action for payment or transfer of value whatsoever with the aim of unduly influencing a civil servant or any natural person and shall not do so in the future.

The Coordinating Investigator represents that there is nothing to prevent him from conducting the Research.

In accordance with Article L1453-1 of the French Public Health Code, the Company is obliged to make public the existence of the agreement and the benefits granted in this context.

The processing of personal data for the purpose of this publication shall be carried out in compliance with the *Loi informatique et Libertés* [French Data Protection Act] of 6 January 1978, as amended.

The Coordinating Investigator shall be entitled to access and rectify the information relating to him.

**CLAUSE 12: CHALLENGES - DISPUTES**

This agreement is governed by French law.

In the event of disagreement as to the interpretation or performance of this agreement, the Parties shall endeavour to settle their dispute amicably.

In the event of persistent disagreement, the court with territorial jurisdiction shall be that of the registered office of the Coordinating Institution in the place where the Research is carried out.

**CLAUSE 13: ANNEXES**

The following annexes are deemed to form an integral part of the agreement:

• Annex 1 – List and contact details of the contact persons within the Company, the Coordinating Institution and, if applicable, the Third-Party Organisation.

• Annex 2 – Procedure for calculating costs and additional costs.

• Annex 3 [Optional] – Compensation relating to the conduct of the Research.

[Place] \_ \_ \_ \_ \_ \_, [date] \_ \_ \_ \_ \_ \_ \_

For the Coordinating Institution For the Company

The Director General

And by delegation



Approval of the Coordinating Investigator:

redacted STATUS Neurologist in the Department/Neurology Unit, of the Limoges University Hospital Health Institution

*“I acknowledge that I have taken note of this Agreement**.”*

**Annex 1 – List and contact details of the contact persons within the Company, the Coordinating Institution and, if applicable, the Third-Party Organisation**

**The referents within the Coordinating Institution for any question concerning Research are:**

Scientific referent, competent in particular for any scientific question concerning the progress of the trial:

**Coordinating Investigator**  
**Name:**    
**Address:**    
  
**Email:**

Administrative Referent, competent in particular for any question concerning the execution of this agreement:

**Name:**  )  
**Address:**

**Email**:

**Phone number:**

**The Company's Referents for any question concerning research are:**

Scientific referent, competent in particular for any scientific question concerning the conduct of the Research:

|  |  |
| --- | --- |
| Name: |  |
| Email: |  |
| Phone number: |  |

Administrative Referent, competent in particular for any question concerning the execution of this agreement:

|  |  |
| --- | --- |
| Name: |  |
| Mailing address: |  |

**Invoicing method for the Company**

*Invoices must be issued to:*

***and***

*should be sent to:*

***Contact details of the recipient of the consignment (name and department) and special information, if necessary***

Invoices will be paid by redacted, whose address is located at redacted, United States, or by the subcontractor of redacted, whose address is redacted, on behalf of redacted

The electronic invoice must include: the Protocol number, the country, the site number, and the name of the investigator on the subject line of the email. Failure to comply with these conditions may delay the processing and payment of the electronically submitted invoice.

**Annex 2 – Procedure for calculating costs and additional costs**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Description of the types of clinical research studies for the purpose of filling out the single agreement template for commercial biomedical research studies** | | | | | |
|  |  |  |  |  |  | |
| Definitions of different types of Research Studies | | | | | |
|  |  |  |  |  |  | |
| **Items:** | | **Research Study Complexity Level:** | | | |
| >2 treatment arms. | |  | | | |
| Phase I/II or pre-CE marking Research Study | | **X** | | | |
| Involving more than 2 Departments and/or Medical-Technical Centers and/or expensive imaging in addition to the pharmacy and Investigator Department. | |  | | | |
| With hospital admission\* (>4 hours) and/or procedure completed under aseptic conditions (sterile area/theatre). | | **X** | | | |
| Collecting multiple PK and/or PD time points and/or molecular screening. | | **X** | | | |
| Completion in expensive facilities (Resuscitation, Intensive care, Palliative care, Surgery, Burns, Transplants, Emergency services, Oncology) | |  | | | |
| Involving a Pediatric Department | |  | | | |
| \* if required by the protocol for medical device (MD) studies. | | | | | |
|  |  |  |  |  |  | |
| **3 levels of Research Study “complexity” corresponding to the number of crosses** | | | | | |
| Level 1 | | <2 | | | |
| Level 2 | | 2 | | | |
| **Level 3** | | **3 or more** | | | |

**Annex 2-1 – method of calculating costs and additional costs**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Template for the calculation of the costs and additional costs for the conduct of the commercial biomedical Research Study** | | | | | | |
|  |  |  |  |  |  |  |
| **Sponsor Company** | Transposon Therapeutics, Inc | | | | | |
| **CRO (if applicable)** | Worldwide Clinical Trials | | | | | |
| **EudraCT or Idrcb Study number** | 2021-002251-11 | | | | | |
| **Name of coordinating or participating Institution** | CHU Dupuytren 1 | | | | | |
| **FINESS number** | 870,000,015,101 | | | | | |
| **Investigator:** | Pr Philippe Couratier | | | | | |
| **Center/Unit** | Neurology | | | | | |
|  |  |  |  |  |  |  |
| **Provisional number of patients for the site** |  |  | 3 |  |  | ***Level 3*** |
|  |  |  |  |  |  |  |
| ***Grid Version 0.1 based on the Protocol dated 08/Jun/2021*** | |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **Evaluation based on:** *Screening (Day -42 to Day -1), InclusionInclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, Unscheduled Visit* | | | | | | |
| **Designation of completed activities and services:** |  |  |  |  |  |  |
|  | **Occurrence limit** | **Cost or additional cost** | **Unit cost €** | **Number of items per patient or per site** | **Total costs for one patient or for the site  €** | **Total for all the patients in the site, or for the site €** |
| **FIXED COSTS** |  |  |  |  |  |  |
| **Fixed administrative costs.** | | | | | |  |
| **Administrative costs:** Research Study registration, Agreement and template development, financial and administrative monitoring of the Agreement, including amendments.  Fixed cost charged per the investigating site and not per Institution. If there are several investigating sites within the Institution, several fixed fees will be invoiced. Invoiced as of the signature date of the Agreement, even if the decision to cancel before starting is attributable to the Sponsor (if the template has already been filled out). | Per Institution €500 Coordinating Center €200 Participating Site | Cost | 500.00 € | 1 | 500.00 € | 500.00 € |
| **Additional costs for drawing up an amendment.** ONLY if the substantial change made to the template is due to a drastic change in the protocol. | Per Institution €100 Coordinating Center €50 Participating Site | Cost | 100.00 € |  | 0.00 € | If applicable |
| **Setting up the Research Study** Site pre-selection, getting to know the protocol and its requirements, feasibility studies, contribution to the development of the template, response to questionnaires in order to verify Good Clinical Practice skills, setup meeting. Fixed cost invoiced even if no patients are included. Invoiced as of the signature of the Agreement. | Per Institution **Level 1 or extension Study:** €300 **Level 2 Study:** €450 **Level 3 Study:** €600 | Cost | 600.00 € | 1 | 600.00 € | 600.00 € |
| **Logistical costs** | | | | | |  |
| **Fixed logistical cost** Telephone, secretariat for arranging appointments, office automation, office stationery, filing Study documents and maintenance of data access . Contribution to the hospital’s functional costs (premises, waste management, sterilization, etc.), contribution to the hospital return on investment, (cost applicable to all patients included prorated to actual screening and inclusions, regardless of the number of visits completed, including if extra visits or procedures are completed over the entire duration of the Study.) *Screening (Day -42 to Day -1), InclusionInclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Cost per patient and per visit **Level 1 Study:** €2/patient/visit **Level 2 Study:** €3/patient/visit **Level 3 Study:** €4/patient/visit Add €1/visit/patient if external staff intervention (excluding Sponsor, CRO, CRA monitoring) | Cost | 4.00 € | 13 | 52.00 € | 156.00 € |
| **Fixed cost for equipment maintenance** (if calibration data given) | Per year of Study ***Based on 2 years, to estimate prorated*** | Cost | 100.00 € | 2 | 200.00 € | 200.00 € |
| **INVESTIGATION TASKS** | | | | | |  |
| **Estimated medical time - hourly cost €85/hour** | | | | | |  |
| **Inclusion consultation** Physician informing the patient and obtaining consent *Screening (Day -42 to Day -1)* | Per patient **Level 1 Study:** €85 **Level 2 Study:**  +0.5 hour, so €127.50 **Level 3 Study:**  +1 hour, so €170 | Cost | 170.00 € | 1 | 170.00 € | 510.00 € |
| Physician informing the patient and obtaining additional consent *if applicable* | Per patient 30 minutes | Cost | 42.50 € |  | 0.00 € | If applicable |
| **Follow-up phone call** 15 minutes, for any type of Research Study.*List the visits* | Per patient | Cost | 21.25 € |  | 0.00 € | 0.00 € |
| **Medical Time** Medical time above common practice: training, specific test/examination, follow-up phone call and those not taken into account by the RBM procedures, hourly, or prorated. *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit) on a pro rata basis* | Per patient | Cost | 85.00 € | 13 | 1,105.00 € | 3,315.00 € |
| **Follow-up Visit** (outside common practice). Specify which ones with the help of the protocol. | Per patient CCAM price | Cost |  |  | 0.00 € | N/A |
| **Sponsor audit excluding pharmacy** From the preparation to the implementation of corrective actions (excluding pharmacy) | Per site €300 per audit if 1 day, and €450 if >1 day | Cost | 300.00 € |  | 0.00 € | If applicable |
| **Estimated Clinical Research Technician (CRT) time - Hourly cost €42/hour** | | | | | |  |
| **CRT training time** **Level 1 Research Study:** 4 or 5 hours (1 hour for paper CRF, 2 hours for eCRF, 1 hour for reading protocol, 1 hour for drawing-up the Department’s procedures, 1 hour for administrative management) **Level 2 Research Study:** 5 or 6 hours (1 hour for paper CRF, 2 hours for eCRF, 2 hours for reading protocol, 1 hour for drawing-up the Department’s procedures, 1 hour for administrative management) **Level 3 Research Study:** 7 or 8 hours (1 hour for paper CRF, 2 hours for eCRF, 3 hours for reading protocol, 2 hours for drawing-up the Department’s procedures, 1 hour for administrative management) | Per staff member | Cost | 336.00 € | 1 | 336.00 € | Prorated |
| **CRT time for monitoring with Sponsor/CRO** Preparation of patient files, availability, answering queries (on average and not per number of patient files) **Level 1 Study:** 2.5 hours per monitoring visit (€105) **Level 2 Study:** 4 hours per monitoring visit (€168) **Level 3 Study:** 5 hours per monitoring visit (€210) | Per visit | Cost | 210.00 € | 1 | 210.00 € | Prorated |
| **CRT time for remote monitoring (audio-conference phone appointment) - 2 hours** | Per appointment | Cost | 84.00 € |  | 0.00 € | Prorated |
| **CRT time for patient screening visit** Visit preparation: organization and planning of protocol procedures, hospitalization, etc., patient information regarding the practicalities of study visits. CRF completion, including collection of patient history, obtaining source information, resolving queries. **Level 1:** 1 hour + 15 minutes per 10 CRF pages **Level 2:** 2 hours + 15 minutes per 5 CRF pages (justification: change of treatment regimen due to the implementation of the trial) **Level 3:** 3 hours + 15 minutes per 5 CRF pages *Screening (Day -42 to Day -1)* | Per patient | Cost | 168.00 € | 1 | 168.00 € | 504.00 € |
| **CRT time for patient follow-up by phone or site visit** Visit organization (including organization and planning of protocol procedures, hospital stay, etc.), CRF data entry, answering queries, adverse events management, specify which with the help of the protocol. **Level 1:** 1 hour + 15 minutes per 10 CRF pages **Level 2:** 2 hours + 15 minutes per 5 CRF pages **Level 3:** 2 hours + 15 minutes per 5 CRF pages *InclusionInclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit) on a pro rata basis* | Per visit | Cost | 126.00 € | 11 | 1,386.00 € | 4,158.00 € |
| **CRT time for final or early termination visit** Visit organization (including organization and planning of protocol procedures, hospital stay, etc.), CRF data entry, resolving queries **Level 1:** 1 hour + 15 minutes per 10 CRF pages **Level 2:** 2 hours + 15 minutes per 5 CRF pages **Level 3:** 2 hours + 15 minutes per 5 CRF pages *Week 48 (Day 337) / Early Termination* | Per visit | Cost | 126.00 € | 1 | 126.00 € | 378.00 € |
| **CRT time for training regarding questionnaires and patient diaries -** 1 hour/protocol | Per Protocol 1 hour | Cost | 42.00 € |  | 0.00 € | 0.00 € |
| **CRT time for management of self-questionnaire or handover and completion of patient questionnaires -** 15 minutes per patient *Screening, InclusionInclusion (Day 1), Week 4 (Day 29), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination* | Per visit | Cost | 10.50 € | 7 | 73.50 € | 220.50 € |
| **CRT time for initial patient training with self-questionnaire -** electronic (1 hour per patient) / paper (30 minutes per patient) | Per patient | Cost | 21.00 € | 1 | 21.00 € | 63.00 € |
| **CRT time for managing sampling kits.** 1 hour/visit **with centralized sample collection** *Screening, Inclusion(Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 /ET, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit/sample)prorated* | Per visit | Cost | 42.00 € | 13 | 546.00 € | 1,638.00 € |
| **Estimated nursing time - Hourly cost €38/hour** | | | | | |  |
| Current nomenclatures take normal patient care into account. Extra nursing time is for carrying out procedures required by the protocol, which are in addition to standard care. => following protocol requirements => following laboratory manual requirements => using the Protocol’s specific kits => completing the protocol’s worksheets, etc. Use of the AMI (doctor/nursing procedure) billing system | | | | | |  |
| **Nursing time for blood sample collection for central analysis -** 15 min *Screening, Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per visit 15 min | Cost | 9.50 € | 13 | 123.50 € | 370.50 € |
| **Nursing time for urine sample collection for central analysis -** 15 min *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit/sample)* | Per visit 15 min | Cost | 9.50 € | 8 | 76.00 € | 228.00 € |
| **Nursing time for the measurement of vital signs** - 15 min *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per visit 15 min | Cost | 9.50 € | 13 | 123.50 € | 370.50 € |
| **Nursing time for ECG** - 15 min *Screening \*3, Inclusion, Week 12\*3, Week 24\*3, Week 32\*3, Week 48\*3 / Early Termination\*3* | Per visit 15 min | Cost | 9.50 € | 16 | 152.00 € | 456.00 € |
| **Nursing time for the injection of study drug** - 15 min*List the visits* | Per visit 15 min | Cost | 9.50 € |  | 0.00 € | 0.00 € |
| **Nursing time for infusion placement and removal** - 30 min*List the visits* | Per visit 30 min | Cost | 19.00 € |  | 0.00 € | 0.00 € |
| **Nursing time for catheter placement and removal** - 30 min*List the visits* | Per visit 30 min | Cost | 19.00 € |  | 0.00 € | 0.00 € |
| **Nursing time for assistance to the physician for dispatch to central laboratory for review** | Per visit | Cost |  |  | 0.00 € | 0.00 € |
| **Nursing time per PK/PD time point** - 15 min | Per visit 15 min | Cost | 9.50 € |  | 0.00 € | 0.00 € |
| **PROCEDURES LISTED IN THE NOMENCLATURE** |  |  |  |  |  |  |
| CSF sampling *Screening, Week 24, Week 48 / Early Termination* | Per procedure  AFHB002 | Additional cost | **34.56 €** | 3 | 103.68 € | 311.04 € |
| ECG (DEQP003) *Screening \*3, Inclusion, Week 12, Week 24, Week 32, Week 48 / Early Termination* | Per ECG DEQP003 | Additional cost | 14.26 € | 8 | 114.08 € | 342.24 € |
| **Blood sample collection** - 1.5 AMI *Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 /ET, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per sample collection 1.5 AMI | Additional cost | 4.73 € | 12 | 56.76 € | 170.28 € |
| **Urine sample collection** 1 AMI | Per sample collection 1 AMI | Additional cost | 3.15 € |  | 0.00 € | 0.00 € |
| **CLINICAL AND MEDICAL/TECHNICAL PROCEDURES NOT LISTED IN THE NOMENCLATURE** | | |  |  |  |  |
| **MMSE** *Screening* | if completed by physician | Cost | 7.08 € | 1 | 7.08 € | 21.25 € |
| if completed by non-physician | Cost | 3.50 € | 3.50 € | If applicable |
| **C-SSRS** *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | if completed by physician | Cost | 14.17 € | 13 | 184.17 € | 552.50 € |
| if completed by non-physician | Cost | 7.00 € | 91.00 € | If applicable |
| **ALSFRS-R + ALSAQ-40 + SVC + CDR plus NACC FTLD-SB + FTD Rating Scale + CBFS + CNS-BFS** *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 4 (Day 29), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination* | if completed by physician | Cost | 85.00 € | 7 | 595.00 € | 1,785.00 € |
| if completed by non-physician | Cost | 42.00 € | 294.00 € | If applicable |
| **Color Trails + Stroop Color and Word Test + MoCA + ALS-CBS + NPI-Q** *Inclusion (Day 1), Week 4 (Day 29), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination* | if completed by physician | Cost | 42.50 € | 6 | 255.00 € | 765.00 € |
| if completed by non-physician | Cost | 21.00 € | 126.00 € | If applicable |
| **HOSPITAL STAY AND CONSULTATIONS** | | | | | |  |
| **Additional medical consultation.** Specific to the clinical trial *Screening, Week 24, Week 48 / ET* | Per consultation Standard consultation (CS), (neuro)psychiatrist or neurologist consultation (CNPSY) or cardiovascular consultation (CSC) | Additional cost | 30.00 € | 3 | 90.00 € | 270.00 € |
| **Fixed accommodation cost < 24 hours**  Costs linked to meals, making a room available, heating, liquids, technical services, medical and nursing monitoring times (fixed costs different from costs for additional procedures linked to the Research Study completed during the day) => the fixed cost must correspond to effective use when the protocol requires a bed or a couch: use isn’t systematic. *Screening, Week 24, Week 48 / Early Termination* | Fixed cost per visit €355 (fixed cost + 1 hour medical time + 1 hour nursing time) | Additional cost | 355.00 € | 3 | 1,065.00 € | 3,195.00 € |
| **Fixed accommodation cost > 24 hours** Costs linked to meals, making a room available, heating, liquids, technical services, medical and nursing monitoring times (fixed costs different from costs for additional procedures linked to the Research Study completed during the day) => the fixed cost must correspond to effective use when the protocol requires a bed or a couch: use isn’t systematic. *not applicable* | Fixed cost per visit €666 (fixed cost + 2 hours medical time + 2 hours nursing time) breakfast (€4 fixed cost included) | Additional cost | 666.00 € |  | 0.00 € | 0.00 € |
| **Meal Fee** *if applicable* | Fixed cost per visit | Additional cost | 4.00 € |  | If applicable | Prorated |
| **OTHER COSTS/ADDITIONAL COSTS ATTRIBUTABLE TO THE TRIAL** | | | | | |  |
| **All unplanned extra costs, which are attributable to the Trial** *Unscheduled Procedures/Visits (for safety reasons, abnormal test results, and/or additional procedures/visits per Protocol will be paid per procedure(s) performed plus staff time)* |  | Cost |  |  | 0.00 € | If applicable |
| **Cost due to a Serious Adverse Event caused by the Research Study:** (managed outside monitoring visits) - 1 hour CRT time and 20 mins medical time | Per SAE  1 hour CRT time and 20 min medical time | Cost | 70.00 € |  | 0.00 € | Prorated |
| **Medical Time** Medical time above common practice: training, specific test/examination, follow-up phone call and procedures not taken into account by the RBM procedures, hourly **Anesthesiologist (CSF sampling) -** *Screening, Week 24, Week 48 / Early Termination* | Per patient | Cost | 85.00 € | 3 | 255.00 € | 765.00 € |
| **CRT time for IVRS/IWRS calls** *Screening, Inclusion* | Per call | Cost | 10.00 € | 2 | 20.00 € | 60.00 € |
| **Fixed cost for research study termination** 1 hour medical time + 3 hours CRT time for Level 3 study | Fixed cost per study | Cost | 211.00 € | 1 | 211.00 € | 211.00 € |
| **Reagents & consumables:** Required by the protocol. Excluding routine analyses. Invoice or total fixed cost/per visit | Per row | Cost |  |  | 0.00 € | 0.00 € |
| **Fixed cost of de-archiving tumor blocks from an external laboratory** (€50 or, if actual cost > €50 upon submission of an invoice) |  | Cost |  |  | 0.00 € | 0.00 € |
| **BIOLOGY - ANATOMIC PATHOLOGY** | | | | | |  |
| **Time for Coordinating Biology/Pathology Research Study** Contribution to: screening, verification of the coordinating template: information: setting up flags, practice changes, results, etc. Training regarding laboratory manual. 1.5 hours/coordinating or participating site (if required by sponsor). | Per site | Cost | 63.00 € | 1 | 63.00 € | 63.00 € |
| **Biology/Pathology Research Study time:** Document transfer (CV, Value ranges (VR), QC, in case of cryostorage: TC (temperature curves), PC (probe calibration), MC (metrology and maintenance controls)) 1.5 hours (if required by protocol). | Per site | Cost | 63.00 € | 1 | 63.00 € | 63.00 € |
| **BIOLOGY – Procedure listed in the nomenclature – NABM RIHN** | | | | | |  |
| **Coagulation test** (prothrombin time and international normalized ratio (INR)  Screening, week 18, week 40 | Per procedure\* B16+B20 | Additional cost | 9.72 € | 3 | 29.16 € | 87.48 € |
| **Hematology CBC (1104) - B25**  including red blood cell count, mean corpuscular hemoglobin concentration in erythrocytes, mean corpuscular erythrocyte volume, hematocrit, hemoglobin, leucocyte count and total monocyte, neutrophil, basophil, eosinophil and platelet count  *Screening, week 24, week 48* | Per procedure\* B25 | Additional cost | 6.75 € | 3 | 20.25 € | 60.75 € |
| **Hematology CBC (known malignant hemopathy monitoring) (1106) - B50** *List the visits* | Per procedure\* B50 | Additional cost | 13.50 € |  | 0.00 € | 0.00 € |
| **Blood pregnancy test (7402) - B26** *Screening* | Per procedure\* B26 | Additional cost | 7.02 € |  | 0.00 € | If applicable |
| **Urine pregnancy test (7401) - B25**  *Inclusion (Day 1), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per procedure\* B25 | Additional cost | 6.75 € | 6 | if applicable | prorated |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **Security cost (9105) - B5** *Inclusion (Day 1), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per procedure\* B5 | Additional cost | 1.35 € | 6 | if applicable | prorated |
| **Pre-analysis costs (9005) - B17** *Inclusion (Day 1), Week 12 (Day 85), Week 24 (Day 169), Week 32 (Day 225), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per procedure\* B17 | Additional cost | 4.59 € | 6 | if applicable | prorated |
| **BIOLOGY - non NABM RIHN procedures** | | | | | |  |
| **Lab technician time Management and technical processing of biological samples** (centrifugation, aliquoting and traceability)  *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit/sample)* | Per visit 1 hour | Additional cost | 42.00 € | 13 | 546.00 € | 1,638.00 € |
| **Lab technician time Management and technical processing of PK blood samples.** Preparation and dispatch to the central laboratory chosen by the sponsor *Screening (Day -42 to Day -1), Inclusion (Day 1), Week 2 (Day 15), Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), Week 18 (Day 127), Week 24 (Day 169), Week 26 (Day 183), Week 32 (Day 225), Week 40 (Day 281), Week 48 (Day 337) / Early Termination, Week 52 (Day 365) / Follow-up Visit, (Unscheduled Visit)* | Per PK time point 30 min | Additional cost | 21.00 € | 13 | 273.00 € | 819.00 € |
| **Lab technician time Specific preparation** (if the preparation is required by the protocol, to be evaluated for the Study) - CSF sample *Screening, Week 24, Week 48 / Early Termination* | Per visit 1 hour | Additional cost | 42.00 € | 3 | 126.00 € | 378.00 € |
| **Lab technician time Specific preparation** (if the preparation is required by the protocol, to be evaluated for the Study) - whole blood sample (10 mL) for future biomedical research *Screening* | Per visit 1 hour | Additional cost | 42.00 € | 1 | 42.00 € | 126.00 € |
| **Fixed cost for storage for research purposes** Storage and transfer of any type of sample (serum plasma, urine, DNA, etc.) if required by the Protocol | Annual fixed cost ***Based on XX years, to price prorated*** | Cost | 200.00 € | NA | NA | NA |
| **BIOLOGY - Procedure not listed in nomenclature** | | | | | |  |
| **Time for setting up an activity, outside routine setup, required by the study in a specialized laboratory** Biologist time: 4 hours x €85 Lab technician time: 4 hours x €42 | Par specialized laboratory/ Study | Cost | 508.00 € | 1 | 508.00 € | 508.00 € |
| **Time for setting up a “Central Lab” activity in the Biology Center/Biological Resource Center (CRB)** Lab technician time: 9 hours x €42 | Par specialized laboratory/ Study | Cost | 378.00 € | 1 | 378.00 € | 378.00 € |
| **Coordination time for setting up an on-call service**: Setup meeting, writing flag and procedure, Training Coord. CRT time: 8 hours x €42 Lab Technician Training Time: 6 hours x2 x €42 | Per site covering this specificity *(following an explicit request from the sponsor) If applicable* | Cost | 840.00 € |  | 0.00 € | 0.00 € |
| **ANATOMIC PATHOLOGY - Procedure listed in CCAM nomenclature** | | | | | |  |
|  |  |  |  |  |  |  |
| **ANATOMIC PATHOLOGY - Procedure not listed in CCAM nomenclature** | | | | | |  |
| **Preparation and dispatch of fresh or archived biopsy** **for centralized review B**lock identification, slide preparation (stained or unstained), management of transfer paperwork (completion and filing) *List the visits* | Per block or biopsy sent | Additional cost | 150.00 € |  | 0.00 € | 0.00 € |
| **Anatomic and Cytologic Pathology (ACP) Physician Time: Expertise; Selection of the biopsy’s block or area of interest before processing and transfer to the central lab.** *List the visits* | Per visit 1.5 hour | Cost | 127.50 € |  | 0.00 € | 0.00 € |
| **Lab technician time Specific preparation** (if the preparation is required by the protocol, to be evaluated for the Study)  *List the visits* |  | Cost |  |  | 0.00 € | 0.00 € |
| **Lab Technician Time for specific processing: slides if >20.** *List the visits* | Per 5 slides (beyond 20) | Cost | 10.00 € |  | 0.00 € | 0.00 € |
| **IMAGING** | | | | | |  |
| **Fixed cost for setting up the trial’s imaging procedures** If the person carrying out the imaging is the principal investigator. An imaging protocol implies a fixed cost for setting up the research study. 4 hours CRT + 1 hour medical | Per site | Cost | 253.00 € |  | 0.00 € | 0.00 € |
| **Fixed cost for complex imaging** if the Protocol requires specific imaging expertise. With justification | Per site | Cost |  |  | 0.00 € | 0.00 € |
| **Review of a procedure carried out outside the site -** 30 minutes medical time | Per test | Cost | 42.50 € |  | 0.00 € | 0.00 € |
| **Fixed cost for specific maintenance** (if not already taken into account) | Per equipment if applicable as part of the protocol | Cost | 100.00 € |  | 0.00 € | If applicable |
| **Specific expert tasks linked to imaging: anonymization/storing data, CD burning.** *List the visits* | Per test 30 min CRT time | Cost | 21.00 € |  | 0.00 € | 0.00 € |
| **Procedures listed in the nomenclature** | | | | | |  |
| **Standard imaging test** (= CCAM base + medication or diagnostic agent (pharmacy price or negotiated price if the agent is for hospital use only)*List the visits* | Per test | Additional cost |  |  | 0.00 € | 0.00 € |
| **Imaging longer than standard or with additional sequences or repetitions or with specific post-treatment** (= CCAM + technical fixed cost + modifier + medication or diagnostic agent (pharmacy price or negotiated price if the agent is for hospital use only)*List the visits* | Per test | Additional cost |  |  | 0.00 € | 0.00 € |
| **Procedures not listed in the nomenclature** | | | | | |  |
| **Test without CCAM = actual cost** *List the visits* | Per test Actual cost | Additional cost |  |  | 0.00 € | 0.00 € |
| **Additional medical time** *for a trial with complex imaging requiring patient care outside standard care - 1 hour medical time* | Per site | Cost | 85.00 € |  | 0.00 € | 0.00 € |
| **Additional CRT time for a trial with complex imaging requiring patient care outside standard care - 4** *hours CRT time* | Per site | Cost | 168.00 € |  | 0.00 € | 0.00 € |
| **CRT time**: sending images via internet platforms or DVD and DTF (Data Transmittal Form) transmission - **30 min CRT time** *List the visits* | Per examination If applicable | Cost | 21.00 € |  | 0.00 € | 0.00 € |
| **CRT time**:  **loading of images taken outside the site on the PACS and file management** - *30 min CRT time* | Per examination If applicable | Cost | 21.00 € |  | 0.00 € | 0.00 € |
| **CRT time for monitoring with sponsor/CRO: preparation of patient files, visit on site -** *2.5 hours CRT time per monitoring visit* | Per monitoring If applicable | Cost | 105.00 € |  | 0.00 € | 0.00 € |
| **CRT time for queries -** *15 min CRT time per item* | Per test | Cost | 10.50 € |  | 0.00 € | 0.00 € |
| **CRT time** *for the management of samples obtained under imaging - 1 hour/sample. (if not taken into account in the anatomic pathology section) List the visits* | Per sample collection If applicable | Cost | 42.00 € |  | 0.00 € | 0.00 € |
| **CRT time for completing CRF -** *15 min/5 pages of completed CRF* | 5 completed CRF pages | Cost | 10.50 € |  | 0.00 € | 0.00 € |
| **Medical time: post-treatment tasks (reconstructions, measurements, etc.) -** *30 min medical time List the visits* | Per test if applicable | Cost | 42.50 € |  | 0.00 € | 0.00 € |
| **Medical time for imaging expertise requested by the sponsor: expertise, intellectual investment, fixed intellectual cost based on a scoring model and quality indicators = all tests including those carried out externally -** *1 hour medical time List the visits* | Per test if applicable | Cost | 85.00 € |  | 0.00 € | 0.00 € |
| **PHARMACY - RADIOPHARMACY - MEDICAL DEVICE** | | | | | |  |
| **Pharmacy or radiopharmacy fixed cost for the first year** | Per site | Cost | 500.00 € | 1 | 500.00 € | 500.00 € |
| **Pharmacy or radiopharmacy fixed cost for subsequent years** | Per site | Cost | 200.00 € |  | 0.00 € | Prorated |
| **Nominative dispensing cost** *Randomisation* | Per prescription | Cost | 28.00 € | 1 | 28.00 € | 84.00 € |
| **Destruction** | As needed | Cost | 8.00 € |  | 0.00 € | Prorated |
| Per campaign | Cost | 80.00 € |  | 0.00 € | Prorated |
| **Special storage requirements** | Per site | Cost | 50.00 € | 1 | 50.00 € | 50.00 € |
| **Labelling or re-labelling.** | <10 units | Cost | 15.00 € |  | 0.00 € | Prorated |
| **Labelling or re-labelling.** | 10-50 units | Cost | 25.00 € |  | 0.00 € | Prorated |
| **Labelling or re-labelling.** | >50 units | Cost | 50.00 € |  | 0.00 € | Prorated |
| **Extra follow-up visit (monitoring) (beyond 6 visits per year)** | Per visit | Cost | 30.00 € |  | 0.00 € | Prorated |
| **IVRS or @VRS procedures** All procedures: receipt, distribution, returns and other procedures validated by this method are concerned, including allocating treatment to the patient. | Per procedure | Cost | 10.00 € |  | 0.00 € | Prorated |
| **Additional receipt/delivery** (beyond 4 per year) | Per receipt/delivery | Cost | 20.00 € |  | 0.00 € | Prorated |
| **Allocating treatment to a patient** (calling a vocal server - IVRS) | Per call | Cost | 10.00 € |  | 0.00 € | 0.00 € |
| **Reconstitution/preparation of medication/assembly of medical device (MD), non-sterile conditions medication and/or MD** *not applicable* | Per procedure | Cost | 20.00 € |  | 0.00 € | 0.00 € |
| **Reconstitution/preparation of medication/assembly of medical device (MD), sterile conditions medication and/or MD** *List the visits* | Per procedure | Cost | 60.00 € |  | 0.00 € | 0.00 € |
| **Constitution + sterilization of a standard tray (MD)** *List the visits* | Per tray | Cost | 60.00 € |  | 0.00 € | 0.00 € |
| **Audits (including preparation time)** Simple internal audit by Sponsor: €200 per audit (if it lasts >4 hours with the actual presence of a pharmacist, €300) This does not include inspections by competent authorities. | Per audit €200 If >4 hours = €300 | Cost |  |  | 0.00 € | If applicable |
| **Specific traceability** One single fixed cost of €70 for the entire trial: BDP, IMD and narcotics | Per site | Cost | 70.00 € | 1 | 70.00 € | 70.00 € |
| **Referencing and entering a Protocol in a prescription software** (only on a case-by-case basis, with justification in case of complex reconstitution of the trial products (e.g., cytotoxic drugs, monoclonal antibodies) | Per site | Cost | 150.00 € | 1 | 150.00 € | 150.00 € |
| **Supply of health products** Purchase of pharmaceutical products, etc. | Per product Purchase price | Additional cost |  |  | 0.00 € | If applicable |
| **Pharmacy - Procedures not listed in the nomenclature** | | | | | |  |
| **Training** (based on pharmacist time at €85/hour or CRT/pharmacy technician time at €42/hour) | pharmacist time at €85/hour | Cost | 85.00 € | 3 | 255.00 € | 255.00 € |
| CRT/pharmacy technician time at €42/hour | Cost | 14.00 € | 1 | 14.00 € | If applicable |
| **Storage/archiving for hospital pharmacy** | Per year of Study Based on 2 years, to be priced prorated | Cost | 10.00 € | 15 | 150.00 € | 150.00 € |
| ***Provided free of charge by the Sponsor*** | | | | | |  |
|  |  |  |  |  |  |  |
| Total cost |  |  |  |  |  | 20,098.25 € |
| Total additional costs |  |  |  |  |  | 7,397.79 € |
| **TOTAL** |  |  |  |  |  | **27,496.04 €** |

**Payment method for the associated establishment**

The payment is to be issued to:

|  |  |  |  |
| --- | --- | --- | --- |
| **RIB** | | | |
|  | | | |
| BENEFICIARY |  | | |
| ESTABLISHMENT |  | | |
| Address |  | | |
| ***National identification*** | | | |
| BANK CODE | SORT CODE | ACCOUNT N° | RIB KEY |
|  |  |  |  |
| ***International identification*** | | | |
| IBAN: |  | | |
| BIC: |  | | |
| **PAYMENT REFERENCE** | DRI REF (87RC….)+Protocol ref. + revenue order number, if applicable | | |

establishment for any questions concerning invoicing:

Name:

Address:

E-mail:

Phone number:

**Annex 3– Compensation relating to the conduct of the Research**

|  |  |  |
| --- | --- | --- |
| Definition of Consideration  specific Annex optional for each health establishment, care home or health centre participating in the research | | |
|  |  |  |
| **Sponsoring company** |  | |
| **CRO company** |  | |
| **Research (Acronym or sponsor reference)** |  | |
| **Health Establishment** |  | |
| **Investigator + study number** |  | |
| **Internal structure concerned (Centre, department, etc.)** | Neurology | |
|  |  |  |
|  |  |  |
| **Recipient of consideration** (sole recipient per signatory establishment) |  |  |
|  |  |  |
| **Allocation of consideration per establishment or third-party structure *(optional)*** | The amounts paid as compensation for inclusion will be paid to a specific financial monitoring unit (UF) (UF Research of the investigator's service). | |
|  |  |  |
|  |  |  |
| **Description** | **Comments/observations** | **Amount of consideration** |
| As per Clause 8 of the Sole Agreement, the Company agrees to pay consideration to the Coordinating Establishment or, where appropriate, the Third-party structure, for the expected quality of data resulting from the Research, as described in Protocol Section 10 DATA QUALITY CONTROL AND QUALITY ASSURANCE. Payment of Consideration will be made following:  - satisfactory Study completion by Study Subjects according to the Protocol;  - satisfactory completion in accordance with the Protocol of all Study Subjects’ CRFs;  - resolution of data questions;  - reconciliation of Investigational Product supplies;  - the return of all Equipment (if applicable) and Study materials; and  - resolution of any other outstanding non-compliance issues (e.g., applicable Essential Documents not provided to CRO/Company within timelines in accordance with Study Instructions). | **Screening** | 84.00 € |
| **Week 0** | 84.00 € |
| **Week 2** | 78.00 € |
| **Week 4** | 78.00 € |
| **Week 8** | 78.00 € |
| **Week 12** | 84.00 € |
| **Week 18** | 78.00 € |
| **Week 26** | 78.00 € |
| **Week 32** | 84.00 € |
| **Week 40** | 78.00 € |
| **Week 48 / ET** | 84.00 € |
| **Week 52** | 78.00 € |
|  | **Total** | **966.00 €** |
|  |  |  |
| **Description** | **Comments/observations** | **Amount of consideration** |
| Pharmacy coordination | **one-time payment** | 250.00 € |
| . Qualitative management of procedures and data: the Clinical Trials Unit (UEC) of the Limoges pharmacy has been ISO 9001 certified since October 2010 (1st in France): -> efficient quality management system: .management of the operating procedure specific to the study describing the pharmaceutical circuit, written by pharmacists, systematically transmitted to the CRA (clinical research associate) of the sponsor as well as to the investigators and CRA of the investigating department before the start of the study, amended if necessary after systematic impact assessment in the event of amendments or other information provided by the sponsor, . Compliance with implementation and activation deadlines. Management of compliant and timely treatments: optimal traceability, IT and in real time thanks to the Pharm Test software® (computerization since 1997) with many possibilities of computer editing during monitoring visits (by product, by patient, balance etc.) | **per year of study** | 700.00 € |

**Terms of payment:**

Payment will be made to the order of:

|  |  |  |  |
| --- | --- | --- | --- |
| **RIB** | | | |
|  | | | |
| HOLDER |  | | |
| ESTABLISHMENT |  | | |
| Address |  | | |
| ***National Identification*** | | | |
| BANK CODE | SORT CODE | ACCOUNT N° | RIB KEY |
|  |  |  |  |
| ***International Identification*** | | | |
| IBAN: |  | | |
| BIC: |  | | |
| **REFERENCE TO BE MENTIONED WHEN PAYING** | REF DRI (87RC….)+Protocol Ref + Revenue title no. if applicable | | |

Contact within the Coordinating Institution for all questions concerning invoicing:

Name:

Address:

Email:

Phone number: